Differential expression analyses on aortic tissue reveal novel genes and pathways associated with abdominal aortic aneurysm onset and progression - Temprano-Sagrera, Gerard; Soto, Begoña; Dilmé, Jaume; Peypoch, Olga; Juscafresa, Laura Calsina; Davtian, David; Nieto, Lluís; Brown, Andrew; Escudero, José Román; Viñuela, Ana; Camacho, Mercedes; Sabater-Lleal, Maria (medRxiv, 2024)
Background Abdominal aortic aneurysms (AAA) are focal dilatations of the abdominal aorta. They are normally asymptomatic and progressively expand, increasing their risk of rupture. Rupture of an AAA is associated with high mortality rates, but the mechanisms underlying the initiation, expansion and rupture of AAA are not yet fully understood. This study aims to characterize and identify new genes associated with the pathophysiology of AAA through differential expression analyses between dilated and non-dilated aortic tissue samples, and between AAA of different diameters. Our study used RNA-seq data on 140 samples, becoming the largest RNA-seq dataset for differential expression studies of AAA.Results We identified 7,454 differentially expressed genes (DEGs) between AAA and controls, 2,851 of which were new compared to previous microarray studies. Notably, a novel cluster on adenosine triphosphate synthesis regulation emerged as strongly associated with AAA. Additionally, exploring AAA of different diameters identified eight genes (EXTL3, ZFR, DUSP8, DISP1, USP33, VPS37C, ZNF784, RFX1) that overlapped with the DEGs between AAA and controls, implying roles in both disease onset and progression. Seven genes (SPP1, FHL1, GNAS, MORF4L2, HMGN1, ARL1, RNASE4) with differential splicing patterns were also DEGs between AAA and controls, suggesting that splicing differences contribute to the observed expression changes and the disease development.Conclusions This study identified new genes and pathways associated with AAA onset and progression and validated previous relevant roles of inflammation and intracellular calcium regulation. These findings provide insights into the complex mechanisms underlying AAA and indicate potential targets to limit AAA progression and mortality risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Spanish Ministry of Science and Innovation (PID2019-109844RB-I00). The genotyping service was carried out at the Genotyping Unit-CEGEN in the Spanish National Cancer Research Centre (CNIO), supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovacion. CEGEN is part of the initiative IMPaCT-GENoMICA (IMP/00009) cofunded by ISCIII and the European Regional Development Fund (ERDF). GT-S is supported by the Pla Estrategic de Recerca i Innovacio en Salut (PERIS) grant from the Catalan Department of Health for junior research personnel (SLT017/20/000100). MS-L is supported by a Miguel Servet contract from the ISCIII Spanish Health Institute (CPII22/00007) and co-financed by the European Social Fund. DD was funded by a Tenovus Scotland Research PhD studentship, T19-06.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hospital de la Santa Creu i Sant Pau Ethics Committee (IIBSP-OMI-2019-102). All patients gave written informed consent prior to surgery to participate in the study. The study conformed to the principles of the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe personal data used for this study is available from the corresponding author on reasonable request for collaborations provided it complies with the ethical permits of the study. All other data supporting the findings of this study is available within the paper and its Supplementary Information. Code used for data preparation and analysis is available at https://github.com/Gerardts9/RNAseq. https://github.com/Gerardts9/RNAseq